[fcb5af]: / literature / by_gene / YY1.tsv

Download this file

# pmid doi year title Hugo_Symbol
1 29564133 10.1186/s40364-018-0126-y 2022 Suitability of Yin Yang 1 transcript and protein levels for biomarker studies in B cell non-Hodgkin lymphoma. YY1
2 34039950 10.1038/s41408-021-00493-5 2022 Genomic insights into the pathogenesis of Epstein-Barr virus-associated diffuse large B-cell lymphoma by whole-genome and targeted amplicon sequencing. YY1
3 35163649 10.3390/ijms23031728 2022 Transcriptional Regulation of Yin-Yang 1 Expression through the Hypoxia Inducible Factor-1 in Pediatric Acute Lymphoblastic Leukemia. YY1
4 32713953 10.24875/BMHIM.19000187 2021 Yin-Yang-1 decreases Fas-induced apoptosis in acute lymphoblastic leukemia under hypoxic conditions: its implications in immune evasion. YY1
5 32899428 10.3390/ijms21176446 2021 Role of the Transcription Factor Yin Yang 1 and Its Selectively Identified Target Survivin in High-Grade B-Cells Non-Hodgkin Lymphomas: Potential Diagnostic and Therapeutic Targets. YY1
6 33179084 10.3892/mmr.2020.11666 2021 Effects and mechanism of microRNA‑218 against lung cancer. YY1
7 33410342 10.1080/10428194.2020.1869960 2021 KLF4 inhibition by Kenpaullone induces cytotoxicity and chemo sensitization in B-NHL cell lines via YY1 independent. YY1
8 33504766 10.1038/s41419-021-03425-0 2021 The DNA-helicase HELLS drives ALK<sup>-</sup> ALCL proliferation by the transcriptional control of a cytokinesis-related program. YY1
9 33544468 10.1515/hsz-2020-0276 2021 PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3. YY1
10 33900899 10.1080/08880018.2020.1871139 2021 Expression of YY1 in pro-B and T phenotypes correlation with poor survival in pediatric acute lymphoblastic leukemia. YY1
11 26622779 10.3892/ol.2015.3498 2020 Role of annexin A6 in cancer. YY1
12 26893685 10.3892/ol.2015.4031 2020 Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study. YY1
13 30277117 10.1080/10428194.2018.1516286 2020 Cytotoxic effect caspase activation dependent of a genetically engineered fusion protein with a CD154 peptide mimetic (OmpC-CD154<sub>p</sub>) on B-NHL cell lines is mediated by the inhibition of bcl-6 and YY1 through MAPK p38 activation. YY1
14 31040909 10.18632/oncotarget.26745 2020 Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma. YY1
15 32236631 10.3892/or.2020.7563 2020 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. YY1
16 33194748 10.3389/fonc.2020.588893 2020 MicroRNA-7 Regulates Migration and Chemoresistance in Non-Hodgkin Lymphoma Cells Through Regulation of KLF4 and YY1. YY1
17 29383875 10.1111/jcmm.13503 2019 Multiple roles of Ring 1 and YY1 binding protein in physiology and disease. YY1
18 29616858 10.1080/10428194.2018.1448083 2019 Role of Yin Yang-1 (YY1) in the transcription regulation of the multi-drug resistance (<i>MDR1</i>) gene. YY1
19 30098214 10.1111/imm.12990 2019 YY1 binds to the E3' enhancer and inhibits the expression of the immunoglobulin κ gene via epigenetic modifications. YY1
20 28724437 10.1186/s12943-017-0692-x 2018 The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. YY1
21 29695404 10.21873/cgp.20080 2018 Establishment and Characteristics of a Novel Mantle Cell Lymphoma-derived Cell Line and a Bendamustine-resistant Subline. YY1
22 28488543 10.1177/1010428317706210 2017 The transcription factor FOXA1 induces epithelial ovarian cancer tumorigenesis and progression. YY1
23 25791160 10.5301/jbm.5000134 2016 Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data. YY1
24 27225481 10.1186/s13046-016-0359-2 2016 Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication. YY1
25 25193702 10.1016/j.bbrc.2014.08.131 2015 Piperlongumine inhibits the proliferation and survival of B-cell acute lymphoblastic leukemia cell lines irrespective of glucocorticoid resistance. YY1
26 24121673 10.1038/ncomms3598 2014 Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. YY1
27 24481661 10.1007/s13277-014-1659-9 2014 Gene set enrichment analysis of the NF-κB/Snail/YY1/RKIP circuitry in multiple myeloma. YY1
28 23757039 10.1136/jclinpath-2013-201461 2013 PLK1 and YY1 interaction in follicular lymphoma is associated with unfavourable outcome. YY1
29 23766940 10.4103/2153-3539.109856 2013 A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. YY1
30 22248058 10.1615/critrevoncog.v16.i3-4.80 2012 Yin Yang 1 in human cancer. YY1
31 22248059 10.1615/critrevoncog.v16.i3-4.90 2012 Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies. YY1
32 22267549 10.1158/1535-7163.MCT-11-0635 2012 Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. YY1
33 21109702 10.1136/jcp.2010.078188 2011 YY1 expression predicts favourable outcome in follicular lymphoma. YY1
34 21133714 10.3109/10428194.2010.531408 2011 A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells. YY1
35 21228036 10.3324/haematol.2010.028605 2011 Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. YY1
36 21282644 10.1073/pnas.1019537108 2011 Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. YY1
37 21411522 10.1128/JVI.02659-10 2011 Valproic acid antagonizes the capacity of other histone deacetylase inhibitors to activate the Epstein-barr virus lytic cycle. YY1
38 20081364 10.4161/cc.9.3.10554 2010 Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression. YY1
39 20425315 10.1007/s11899-006-0001-z 2010 What signals are generated by anti-CD20 antibody therapy? YY1
40 19188155 10.1158/1078-0432.CCR-08-1685 2009 In vivo model of follicular lymphoma resistant to rituximab. YY1
41 19513562 10.3892/ijo_00000323 2009 Combination treatment of malignant B cells using the anti-CD20 antibody rituximab and the anti-malarial artesunate. YY1
42 19861448 10.1158/1078-0432.CCR-09-1234 2009 Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. YY1
43 17973241 10.1002/path.2258 2008 The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma. YY1
44 17255358 10.1182/blood-2006-09-046391 2007 Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling. YY1
45 17287852 10.1038/sj.leu.2404583 2007 Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer. YY1
46 17530016 10.1038/sj.onc.1210365 2007 Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. YY1
47 17641042 10.4049/jimmunol.179.3.1760 2007 OX40 gene expression is up-regulated by chromatin remodeling in its promoter region containing Sp1/Sp3, YY1, and NF-kappa B binding sites. YY1
48 16103877 10.1038/sj.onc.1208954 2006 Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. YY1
49 16147992 10.1074/mcp.M500112-MCP200 2006 Analysis of BCL6-interacting proteins by tandem mass spectrometry. YY1
50 16081784 10.4049/jimmunol.175.4.2174 2005 Rituximab-induced inhibition of YY1 and Bcl-xL expression in Ramos non-Hodgkin's lymphoma cell line via inhibition of NF-kappa B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively. YY1
51 14707079 10.4049/jimmunol.172.2.1054 2004 NF-kappa B and Oct-2 synergize to activate the human 3' Igh hs4 enhancer in B cells. YY1
52 14982841 10.1016/S0002-9440(10)63175-6 2004 Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. YY1
53 12393438 10.1182/blood-2002-04-1207 2003 The gene encoding the transcriptional regulator Yin Yang 1 (YY1) is a myeloid transforming gene interfering with neutrophilic differentiation. YY1
54 12954229 10.1016/s0042-6822(03)00379-9 2003 Triple basepair changes within and adjacent to the conserved YY1 motif upstream of the U3 enhancer repeats of SL3-3 murine leukemia virus cause a small but significant shortening of latency of T-lymphoma induction. YY1
55 10680598 10.1016/s0304-3835(99)00321-3 2000 Analysis of highly frequent allelic loss region on distal chromosome 12 in murine radiation-induced lymphomas. YY1
56 10858540 10.1016/s0167-4781(00)00098-1 2000 Early steps in termination of the immortalization state in Burkitt lymphoma: induction of genes involved in signal transduction, transcription, and trafficking by the ganglioside IV(3)NeuAc-nLcOse(4)Cer. YY1
57 8756632 10.1128/MCB.16.9.4744 1996 The nuclear factor YY1 suppresses the human gamma interferon promoter through two mechanisms: inhibition of AP1 binding and activation of a silencer element. YY1